Industry News
Pharmaceutical Industry News
I Consulted With Christa Pike’s Death Row Team. I Knew This Could Happen.
Lethal injection failures are not glitches; they are features of the process.
Scientists Untangle the Biology of an ‘Undruggable’ Cancer Gene
Found in 70 percent of cancers, the gene is seen as a grand orchestrator but has been surprisingly difficult to stop.
America Wants to Make More Generic Drugs. India Shows Why That’s Hard.
Cheap labor and global supply chains are among the obstacles to President Trump’s plan to bring generic drug manufacturing back home.
How Did Christa Pike Survive Two Lethal Injections of Pentobarbital?
A catheter carrying the drug may not have delivered the doses to Ms. Pike’s bloodstream, experts said. The drug itself may have been degraded.
Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working
Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib.
New Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?
Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.
Why Do Clinical Trials for Cancer Drugs Take So Long?
Readers respond to a guest essay about the costs and delays in getting experimental treatments to patients.
An Idaho Cold Case Revisits the Unsolved Tylenol Killings in 1982
A man who killed himself that year in a church in Boise was known as the “Unknown Wanderer.” Investigators said he might have a connection to the famous case of tainted Tylenol.
GSK showed a “totally…
GSK showed a “totally unacceptable” lack of transparency in its interactions with the PMCPA, the U.K. self-regulatory body ruled.
Boehringer Ingelheim is bidding…
Boehringer Ingelheim is bidding adieu to its biologics contract manufacturing unit in China, inking a small-scale deal that gives local developer Raas Blood Products an established biologics production base for its lead antibody drug candidate.
The FDA has green-lighted…
The FDA has green-lighted Elevar’s FGFR2-selective inhibitor Lyrfigtu in bile duct cancer, making it the first novel cancer drug from a Korean company to secure FDA approval.
Glaukos is teaming up with…
Glaukos is teaming up with four-time NBA champion, two-time NBA Most Valuable Player and Olympic gold medalist Stephen Curry for a new “Could it be KC?” campaign.
Otsuka ICU Medical, a joint…
Otsuka ICU Medical, a joint venture from Japan’s Otsuka Pharmaceutical Factory, issued a voluntary recall of one lot of 0.9% sodium chloride injection for IV due to a possible mix-up of labels.
Have GLP-1 Drugs Changed How You Travel? Tell Us About It.
The New York Times wants to know how a GLP-1 medication may have affected how readers plan vacations.
Biogen has teamed with gymnast…
Biogen has teamed with gymnast Suni Lee for a campaign, leveraging the Olympic gold medalist’s health journey and social media audience to vault deeper into kidney health awareness.
The Ozempic and Wegovy maker’s CEO…
The Ozempic and Wegovy maker's CEO said he's open to a direct listing of Novo's shares on the New York Stock Exchange, but no such transition is currently underway.
Sign-ups for Medicare’s GLP-1…
Sign-ups for Medicare’s GLP-1 coverage plan keep expanding, and Eli Lilly is dominating the market with 70% share, the company’s CEO David Ricks said.
Despite hitting a speed bump over…
Despite hitting a speed bump over the summer, automated cell therapy manufacturing specialist Cellares has continued to sign new partners at a steady pace, now inking a second agreement with an Asia-based organization in just
AstraZeneca has re-upped its…
AstraZeneca has re-upped its UNICEF-partnered Young Health Programme, committing to a new five-year phase that will move total investment in the initiative above $100 million.
Hayden Panettiere’s Death Caused by Overdose of Fentanyl and Other Drugs
Ms. Panettiere, who starred in “Heroes” and “Nashville,” died last month at the age of 36. Her death was ruled accidental.